Neumora Therapeutics (NASDAQ:NMRA) Stock Price Up 8.2% – What’s Next?

Neumora Therapeutics, Inc. (NASDAQ:NMRA) was up 8.2% on Tuesday . The company traded as high as $3.51 and last traded at $3.4850. Approximately 258,784 shares traded hands during mid-day trading, a decline of 86% from the average daily volume of 1,882,514 shares. The stock had previously closed at $3.22.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on NMRA shares. Royal Bank Of Canada upgraded Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and boosted their price objective for the company from $4.00 to $7.00 in a research note on Monday, December 1st. Mizuho set a $6.00 price target on shares of Neumora Therapeutics in a research report on Monday, January 5th. Stifel Nicolaus increased their target price on Neumora Therapeutics from $2.00 to $3.00 and gave the stock a “hold” rating in a research report on Monday, November 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neumora Therapeutics in a research report on Thursday, January 22nd. Finally, Leerink Partners started coverage on Neumora Therapeutics in a research note on Monday, January 12th. They set an “outperform” rating and a $8.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $6.71.

Neumora Therapeutics Trading Up 6.5%

The stock has a market cap of $572.95 million, a P/E ratio of -2.33 and a beta of 2.46. The firm’s fifty day moving average price is $2.53 and its two-hundred day moving average price is $2.21. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.85 and a quick ratio of 6.85.

Insider Buying and Selling

In other news, insider Paul L. Berns sold 9,819 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $3.51, for a total transaction of $34,464.69. Following the completion of the transaction, the insider owned 7,395,185 shares of the company’s stock, valued at approximately $25,957,099.35. The trade was a 0.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 23,387 shares of company stock worth $82,647 in the last three months. 26.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Legacy Private Trust Co. lifted its position in Neumora Therapeutics by 35.7% in the 4th quarter. Legacy Private Trust Co. now owns 19,000 shares of the company’s stock worth $34,000 after buying an additional 5,000 shares during the last quarter. Vanguard Personalized Indexing Management LLC boosted its stake in Neumora Therapeutics by 10.7% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 64,429 shares of the company’s stock worth $117,000 after buying an additional 6,233 shares in the last quarter. Invesco Ltd. grew its position in Neumora Therapeutics by 6.8% during the second quarter. Invesco Ltd. now owns 132,038 shares of the company’s stock valued at $97,000 after acquiring an additional 8,383 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Neumora Therapeutics in the 3rd quarter valued at $31,000. Finally, Barclays PLC lifted its stake in Neumora Therapeutics by 202.0% in the fourth quarter. Barclays PLC now owns 30,924 shares of the company’s stock worth $55,000 after purchasing an additional 20,683 shares during the last quarter. 47.65% of the stock is currently owned by hedge funds and other institutional investors.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.